REGENERON PHARMACEUTICALS, INC. Funds and ETFs Regeneron Pharmaceuticals, Inc.
Equities
REGN
US75886F1075
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 906.5 USD | -0.09% |
|
+1.39% | +3.22% |
ETFs positioned on Regeneron Pharmaceuticals, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.27% | 0 M€ | 0.00% | - | |
| 7.08% | 0 M€ | 0.00% | - | |
| 4.02% | 1 M€ | 0.00% | - | |
| 2.56% | 8 M€ | -.--% | ||
| 1.90% | 18 M€ | +4.24% | - | |
| 1.85% | 2 M€ | +5.19% | ||
| 1.65% | 9 M€ | -4.31% | - | |
| 1.62% | 2 M€ | -25.75% | ||
| 1.33% | 26 M€ | +16.85% | - | |
| 1.13% | 9 M€ | +15.45% | - | |
| 1.06% | 1 M€ | 0.00% | - | |
| 1.02% | 16 M€ | -6.73% | ||
| 1.02% | 1,182 M€ | +0.53% | ||
| 1.01% | 1 M€ | +16.32% | ||
| 1.00% | 204 M€ | +10.54% | ||
| 0.94% | 11 M€ | -6.03% | - | |
| 0.79% | 10 M€ | +5.63% | ||
| 0.78% | 282 M€ | +3.15% | - | |
| 0.77% | 9 M€ | -.--% | - | |
| 0.74% | 92 M€ | +0.06% | - | |
| 0.72% | 22 M€ | 0.00% | - | |
| 0.72% | 5 M€ | -72.95% | - | |
| 0.71% | 3 M€ | 0.00% | - |
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
906.5
USD
Average target price
1,036
USD
Spread / Average Target
+14.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.22% | 97.5B | |
| -1.51% | 105B | |
| +1.86% | 22.19B | |
| -16.53% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.09% | 14.52B | |
| +5.47% | 14.09B | |
| +28.85% | 10.99B | |
| -24.93% | 8.63B |
- Stock Market
- Equities
- REGN Stock
- Funds and ETFs Regeneron Pharmaceuticals, Inc.
